IL321935A - Treatment of CD20-positive B-cell lymphoma with obinutuzumab - Google Patents

Treatment of CD20-positive B-cell lymphoma with obinutuzumab

Info

Publication number
IL321935A
IL321935A IL321935A IL32193525A IL321935A IL 321935 A IL321935 A IL 321935A IL 321935 A IL321935 A IL 321935A IL 32193525 A IL32193525 A IL 32193525A IL 321935 A IL321935 A IL 321935A
Authority
IL
Israel
Prior art keywords
obinutuzumab
hour
administration
cycle
pharmaceutical composition
Prior art date
Application number
IL321935A
Other languages
English (en)
Hebrew (he)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64362606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL321935(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL321935A publication Critical patent/IL321935A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
IL321935A 2017-10-19 2018-10-19 Treatment of CD20-positive B-cell lymphoma with obinutuzumab IL321935A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574297P 2017-10-19 2017-10-19
PCT/JP2018/038924 WO2019017499A2 (en) 2017-10-19 2018-10-19 PHARMACEUTICAL COMPOSITION

Publications (1)

Publication Number Publication Date
IL321935A true IL321935A (en) 2025-09-01

Family

ID=64362606

Family Applications (2)

Application Number Title Priority Date Filing Date
IL321935A IL321935A (en) 2017-10-19 2018-10-19 Treatment of CD20-positive B-cell lymphoma with obinutuzumab
IL273909A IL273909B2 (en) 2017-10-19 2018-10-19 Treatment of cd20-positive b-cell lymphoma with obituzumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL273909A IL273909B2 (en) 2017-10-19 2018-10-19 Treatment of cd20-positive b-cell lymphoma with obituzumab

Country Status (14)

Country Link
US (2) US12129304B2 (enExample)
EP (2) EP3697818B1 (enExample)
JP (2) JP6860652B2 (enExample)
KR (3) KR102906969B1 (enExample)
CN (2) CN111212854A (enExample)
AU (2) AU2018303836B2 (enExample)
BR (1) BR112020007731A2 (enExample)
CA (1) CA3079374A1 (enExample)
ES (1) ES3005784T3 (enExample)
IL (2) IL321935A (enExample)
MX (2) MX419643B (enExample)
PL (1) PL3697818T3 (enExample)
TW (2) TWI805630B (enExample)
WO (1) WO2019017499A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3697818B1 (en) * 2017-10-19 2024-11-27 F. Hoffmann-La Roche AG Treatment of cd20-positive b-cell lymphoma with obinutuzumab
US20240050562A1 (en) * 2019-10-04 2024-02-15 Chugai Seiyaku Kabushiki Kaisha Inhibitor of cell proliferation in obinutuzumab resistant cd20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type ii anti-cd20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto
EP4404430A4 (en) 2021-09-17 2025-10-29 Canon Kk POWER TRANSMISSION DEVICE AND POWER RECEPTION DEVICE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
DK2234600T3 (da) 2007-12-21 2014-09-08 Hoffmann La Roche Antistofformulering
SI3179992T1 (sl) * 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
US11149091B2 (en) * 2015-12-09 2021-10-19 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
JP6881583B2 (ja) 2017-07-21 2021-06-02 横浜ゴム株式会社 空気入りタイヤ
EP3697818B1 (en) * 2017-10-19 2024-11-27 F. Hoffmann-La Roche AG Treatment of cd20-positive b-cell lymphoma with obinutuzumab

Also Published As

Publication number Publication date
CN120983618A (zh) 2025-11-21
WO2019017499A2 (en) 2019-01-24
JP6860652B2 (ja) 2021-04-21
TWI828593B (zh) 2024-01-01
WO2019017499A3 (en) 2019-02-21
CA3079374A1 (en) 2019-01-24
EP3697818B1 (en) 2024-11-27
BR112020007731A2 (pt) 2020-10-20
PL3697818T3 (pl) 2025-03-24
AU2018303836A1 (en) 2020-05-14
US20250026847A1 (en) 2025-01-23
TW202342099A (zh) 2023-11-01
AU2018303836B2 (en) 2025-04-17
KR102906969B1 (ko) 2026-01-05
IL273909A (en) 2020-05-31
KR20200067196A (ko) 2020-06-11
KR20260011191A (ko) 2026-01-22
KR20240157135A (ko) 2024-10-31
EP3697818A2 (en) 2020-08-26
US12129304B2 (en) 2024-10-29
IL273909B2 (en) 2025-12-01
JP2019528282A (ja) 2019-10-10
IL273909B1 (en) 2025-08-01
TW201922284A (zh) 2019-06-16
AU2025205481A1 (en) 2025-08-07
ES3005784T3 (en) 2025-03-17
MX2024009217A (es) 2024-11-08
EP4520347A3 (en) 2025-06-04
JP7370357B2 (ja) 2023-10-27
TWI805630B (zh) 2023-06-21
EP4520347A2 (en) 2025-03-12
JP2021152002A (ja) 2021-09-30
MX2020003418A (es) 2020-07-20
MX419643B (es) 2025-01-14
KR102766089B1 (ko) 2025-02-13
CN111212854A (zh) 2020-05-29
US20200299398A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
JP2011511072A5 (enExample)
RU2018120377A (ru) Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
JP7491220B2 (ja) 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療
HRP20230504T1 (hr) Antagonisti aktivin-actrii i upotreba u liječenju mijelodisplastičnog sindroma
IL263110B (en) Combined treatment of notch and pd-1 or pd-l1 inhibitors
JP2018520094A5 (enExample)
JP2010515709A5 (enExample)
IL321935A (en) Treatment of CD20-positive B-cell lymphoma with obinutuzumab
CN108601831A (zh) 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途
JP2019514974A5 (enExample)
CN102006875A (zh) 吡铂和贝伐单抗治疗结直肠癌的用途
JP2019514858A5 (enExample)
EP4549467A2 (en) Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
RU2020134307A (ru) Режимы дозирования мелфлуфена для раковых заболеваний
JP2021152002A5 (enExample)
TW202227089A (zh) 用於治療ｐｉｋ３ｃａ突變癌症的組合療法
JP2017527551A5 (enExample)
Kim et al. Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer
Wolf et al. Peripheral administration of antithymocyte globulins: a review of current literature
CN102327599A (zh) 用于治疗骨髓增生异常综合征的组合物和方法
JP2020172471A (ja) ヒト化抗ヒトｃｄ２６抗体を含有する医薬組成物
Starr Isatuximab plus RVd Combination Achieves High Rates of No MRD in Patients with Multiple Myeloma.
Aoki Elevated intraocular pressure: 2 case reports
HK40125832A (en) Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
Vial Respiratory Syncytial Virus (RSV)